Compare TARS & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TARS | VERA |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 2020 | 2021 |
| Metric | TARS | VERA |
|---|---|---|
| Price | $61.92 | $43.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $89.00 | $81.30 |
| AVG Volume (30 Days) | 529.2K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.21 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $451,360,000.00 | N/A |
| Revenue This Year | $56.43 | N/A |
| Revenue Next Year | $30.19 | $472.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $38.51 | $19.07 |
| 52 Week High | $85.25 | $56.05 |
| Indicator | TARS | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 74.10 |
| Support Level | $60.95 | $37.54 |
| Resistance Level | $66.36 | $47.00 |
| Average True Range (ATR) | 2.83 | 1.94 |
| MACD | 0.40 | 1.16 |
| Stochastic Oscillator | 28.21 | 99.04 |
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.